New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care
Categories
Pivotal Studies for KEYTRUDA® (pembrolizumab) in Esophageal Cancer (KEYNOTE-590) and LYNPARZA® (olaparib) in Prostate Cancer (PROfound) Selected for ESMO Presidential Symposium Sessions